At a glance
ClinicalIndex Comparison RecordN/ACompleted· 25 enrolled
Drug / intervention
Radiation therapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Glottic Larynx Stereotactic Ablative Radiotherapy (LT-SABR) for Early-Stage Glottic Larynx Cancer
University of Texas Southwestern Medical Center·interventional·Posted Jun 7, 2018·Updated May 22, 2025
In Brief
A clinical study evaluating Radiation therapy for Glottic Carcinoma. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This is a prospective study to determine the local control and quality-of-life outcomes of using SBRT for early-stage glottic larynx cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlottic Carcinoma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedJun 2018
Primary CompletionApr 2023
Study CompletionApr 2024
TodayJul 2026
First PostedJun 7, 2018
Enrollment StartMay 15, 2018
Primary CompletionApr 25, 2023
Study CompletionApr 30, 2024
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 8.1 years ago
Interventions
Radiation therapyradiation
Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)